GlassScriptPhysician profile
Alyssa M Jack
NPI 1598357436
$3,292.63
in general payments reported to CMS, 2019-2025
25 companies · $1,141 in 2025
The $1,141 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $45.94 · 2022: $47.17 · 2023: $252 · 2024: $1,807 · 2025: $1,141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,927 · Education: $273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,926.58 |
| Education | $272.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $912.88 | 2023-2025 | Enbrel, Tavneos, Otezla |
| Ucb, INC. | $645.04 | 2023-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $393.81 | 2024-2025 | Taltz, Zepbound, Mounjaro |
| Janssen Biotech, INC. | $380.52 | 2024-2025 | Tremfya |
| Novartis Pharmaceuticals Corporation | $221.01 | 2024-2025 | |
| Abbvie INC. | $127.29 | 2021-2024 | |
| E.R. Squibb & Sons, L.L.C. | $79.51 | 2024 | |
| Novo Nordisk INC | $68.44 | 2023 | Wegovy |
| Mallinckrodt Hospital Products INC. | $64.18 | 2024-2025 | Acthar |
| Ani Pharmaceuticals, INC. | $55.47 | 2024-2025 | Purified Cortrophin Gel |
| Actelion Pharmaceuticals US, INC. | $45.81 | 2022-2023 | Opsumit, Uptravi |
| Glaxosmithkline, LLC. | $39.60 | 2024 | Nucala, Benlysta |
| Pfizer INC. | $38.17 | 2024 | |
| Xeris Pharmaceuticals, INC. | $34.09 | 2025 | Gvoke Hypopen |
| Alexion Pharmaceuticals, INC. | $26.94 | 2025 | Ultomiris |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Radius Health, INC. | $19.95 | 2024 | Tymlos |
| Kiniksa Pharmaceuticals International, Plc | $19.59 | 2024 | Arcalyst |
| Kyowa Kirin, INC. | $18.73 | 2024 | Crysvita |
| Arbor Pharmaceuticals, INC. | $17.35 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $15.11 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $14.36 | 2022 | |
| Pacira Pharmaceuticals Incorporated | $14.30 | 2024 | Iovera, Zilretta, Exparel |
| Boston Scientific Corporation | $13.94 | 2024 | |
| Genentech USA, INC. | $13.28 | 2024 | Actemra |
| Sobi, INC | $13.26 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alyssa Jack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.